PharmaShots | Incisive News in 3 Shots

Subscribe Now

High Hepatocellular Carcinoma Patients

Eli Lilly Reports Results of Cyramza (ramucirumab) in P-III REACH 2 study for 2L AFP-High HCC- Published in The Lancet

Eli Lilly Reports Results of Cyramza (ramucirumab) in P-III REACH 2 study for 2L AFP-High HCC- Published in The Lancet

January 22, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us